This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year
by Zacks Equity Research
Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis
Find 'Strong Buy' Stocks Near Highs Amid Volatility
by Benjamin Rains
Given this backdrop, investors might want to consider buying stocks that have remained near their highs amid the volatility...
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
by Zacks Equity Research
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
4 Biotech Stocks That Have Already Doubled This Year So Far
by Kinjel Shah
Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.
Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod
by Zacks Equity Research
The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.
Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.
Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Company News for May 11, 2021
by Zacks Equity Research
Companies in the news are: BNTX, WB, ES, J
The Zacks Analyst Blog Highlights: BioNTech, Western Digital and Orient Overseas International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioNTech, Western Digital and Orient Overseas International
3 Fast-Moving Stocks: Global Week Ahead
by John Blank
Most central banks are not yet unwinding money-printing or raising rates, but money supply growth has shrunk. And just how transitory will inflation be?
Stock Market News for May 7, 2021
by Zacks Equity Research
Wall Street closed sharply higher on Thursday following strong labor market Data.
Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.
Panasonic (PCRFY) to Post FY2021 Earnings: What's in Store?
by Zacks Equity Research
Despite accretive collaborations and profitability enhancement endeavors, Panasonic's (PCRFY) fiscal-year 2021 earnings are likely to have been hurt by lower revenues, fueled by COVID-19 adversities.
Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.
Q1 Earnings Season Maintains its Momentum
by Zacks Equity Research
Q1 Earnings Season Maintains its Momentum.
Pfizer, UnderArmour Beat; Trade Deficit at All-Time Low
by Mark Vickery
A sense of caution has begun to permeate the market off near-all-time highs in the indexes, and Pfizer looks to be a recipient of this today.
BioNTech SE Sponsored ADR (BNTX) Stock Jumps 11%: Will It Continue to Soar?
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, which has been developed in partnership with Pfizer.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Will Pfizer (PFE) Deliver a Beat This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.
Find Strong Stocks During Earnings Season with this First Profit Screener
by Benjamin Rains
Let's use our 'First Profit' screener to help find strong stocks to consider buying...